RAB32 and glioblastoma: Since the isocitrate dehydrogenase 1 and 2 (IDH-1/2) mutation status is served as a critical biomarker for the guidance of the diagnosis and prognosis, and high-grade GBM with IDH1 mutations have a relatively better prognosis than IDH1 wild-type [22], we then checked the Rab32 protein level in both IDH1mutant and wild-type GBMs.